Kazakhstan's radiopharmaceutical shows positive results in treating bone metastases
Kazakhstan is expanding its capacity to support cancer patients through the development of domestic radiopharmaceuticals, Qazinform News Agency reports.
At the Nuclear Medicine Center of the Medical Center Hospital of the Presidential Administration, doctors continue to use the radiopharmaceutical Samarium-153 Sm Oxabifor to treat bone metastases.
Since its introduction in late 2024, more than 50 patients have received treatment.
Head of the Nuclear Medicine Center Aigul Saduakassova noted, the development of radiopharmaceutical therapy reveals new prospects in treating cancers.
She stressed clinical observations and follow-up studies show pain reduction and positive dynamics in bone metastases.
The main therapeutic effect is a significant decrease in pain intensity, allowing patients to maintain daily activity and improve overall well-being.
She noted that the method demonstrates both pain relief and reduction of metastatic lesions, confirming its effectiveness and importance in cancer care.
Patients report substantial improvements in quality of life.
One of the advantages is that it can be combined with chemotherapy, targeted therapy, hormonal therapy, and immunotherapy. To note, it requires no lengthy recovery period and has minimal serious side effects.
The introduction of Samarium-153 Sm Oxabifor marks an important stage in the development of Kazakhstan’s nuclear medicine. Experience gained over the past year shows that modern radiopharmaceutical technologies can effectively complement existing cancer treatments and significantly improve patients’ quality of life.
Earlier it was reported, Kazakhstan to register its first homegrown cancer drug by year-end.
